NCT06570369View on ClinicalTrials.gov

A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 22, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Major Depressive DisorderDepressionHealthy
Interventions
DRUG

SP-624

Oral dose, once daily for 2 weeks

DRUG

Placebo

Oral dose, once daily for 2 weeks

Trial Locations (2)

68526

Alivation Research, Lincoln

92845

CenExel CNS, Garden Grove

All Listed Sponsors
lead

Sirtsei Pharmaceuticals, Inc.

INDUSTRY

NCT06570369 - A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression | Biotech Hunter | Biotech Hunter